Literature DB >> 26202985

Radiosensitive Hematopoietic Cells Determine the Extent of Skin Inflammation in Experimental Epidermolysis Bullosa Acquisita.

Hiroaki Iwata1, Mareike Witte2, Unni Krishna S R L Samavedam2, Yask Gupta2, Atsushi Shimizu3, Akira Ishiko3, Tobias Schröder2, Karsten Seeger4, Markus Dahlke5, Dirk Rades5, Detlef Zillikens6, Ralf J Ludwig7.   

Abstract

Animal models have enhanced our understanding of the pathogenesis of autoimmune diseases. For these models, genetically identical, inbred mice have commonly been used. Different inbred mouse strains, however, show a high variability in disease manifestation. Identifying the factors that influence this disease variability could provide unrecognized insights into pathogenesis. We established a novel Ab transfer-induced model of epidermolysis bullosa acquisita (EBA), an autoimmune disease characterized by (muco)-cutaneous blistering caused by anti-type VII collagen (COL7) autoantibodies. Blistering after anti-COL7 IgG (directed against the von Willebrand factor A-like domain 2) transfer showed clear variability among inbred mouse strains, that is, severe cutaneous blistering and inflammation in C57BL/6J and absence of skin lesions in MRL/MpJ mice. The transfer of anti-COL7 IgG into irradiated, EBA-resistant MRL/MpJ mice, rescued by transplantation with bone marrow from EBA-susceptible B6.AK-H2k mice, induced blistering. To the contrary, irradiated EBA-susceptible B6.AK-H2k mice that were rescued using MRL/MpJ bone marrow were devoid of blistering. In vitro, immune complex activation of neutrophils from C57BL/6J or MRL/MpJ mice showed an impaired reactive oxygen species release from the latter, whereas no differences were observed after PMA activation. This finding was paralleled by divergent expression profiles of immune complex-activated neutrophils from either C57BL/6J or MRL/MpJ mice. Collectively, we demonstrate that radiosensitive cells determine the varying extent of skin inflammation and blistering in the end-stage effector phase of EBA.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202985     DOI: 10.4049/jimmunol.1501003

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis.

Authors:  William R Swindell; Kellie A Michaels; Andrew J Sutter; Doina Diaconu; Yi Fritz; Xianying Xing; Mrinal K Sarkar; Yun Liang; Alex Tsoi; Johann E Gudjonsson; Nicole L Ward
Journal:  Genome Med       Date:  2017-03-09       Impact factor: 11.117

2.  Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Unni K Samavedam; Nina Mitschker; Anika Kasprick; Katja Bieber; Enno Schmidt; Tamás Laskay; Andreas Recke; S Goletz; Gestur Vidarsson; Franziska S Schulze; Mikko Armbrust; Katharina Schulze Dieckhoff; Hendri H Pas; Marcel F Jonkman; Kathrin Kalies; Detlef Zillikens; Yask Gupta; Saleh M Ibrahim; Ralf J Ludwig
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

3.  Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Hiroshi Koga; Anika Kasprick; Rosa López; Mariona Aulí; Mercè Pont; Núria Godessart; Detlef Zillikens; Katja Bieber; Ralf J Ludwig; Cristina Balagué
Journal:  Front Immunol       Date:  2018-07-12       Impact factor: 7.561

4.  A Mitochondrial Polymorphism Alters Immune Cell Metabolism and Protects Mice from Skin Inflammation.

Authors:  Paul Schilf; Axel Künstner; Michael Olbrich; Silvio Waschina; Beate Fuchs; Christina E Galuska; Anne Braun; Kerstin Neuschütz; Malte Seutter; Katja Bieber; Lars Hellberg; Christian Sina; Tamás Laskay; Jan Rupp; Ralf J Ludwig; Detlef Zillikens; Hauke Busch; Christian D Sadik; Misa Hirose; Saleh M Ibrahim
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 5.  Milestones in Personalized Medicine in Pemphigus and Pemphigoid.

Authors:  Katja Bieber; Khalaf Kridin; Shirin Emtenani; Katharina Boch; Enno Schmidt; Ralf J Ludwig
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

6.  Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita.

Authors:  Stefan Tukaj; Jagoda Mantej; Krzysztof Sitko; Detlef Zillikens; Ralf J Ludwig; Katja Bieber; Michael Kasperkiewicz
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 7.  The relevance of complement in pemphigoid diseases: A critical appraisal.

Authors:  Cristian Papara; Christian M Karsten; Hideyuki Ujiie; Enno Schmidt; Leon F Schmidt-Jiménez; Adrian Baican; Patricia C Freire; Kentaro Izumi; Katja Bieber; Matthias Peipp; Admar Verschoor; Ralf J Ludwig; Jörg Köhl; Detlef Zillikens; Christoph M Hammers
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

8.  Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.

Authors:  Saeedeh Ghorbanalipoor; Shirin Emtenani; Melissa Parker; Mayumi Kamaguchi; Colin Osterloh; Manuela Pigors; Natalie Gross; Stanislav Khil'chenko; Anika Kasprick; Sabrina Patzelt; Diana Wortmann; Ibrahim O Ibrahim; Kentaro Izumi; Stephanie Goletz; Katharina Boch; Kathrin Kalies; Katja Bieber; Paul Smith; Enno Schmidt; Ralf J Ludwig
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

9.  Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Authors:  Sidonia Mihai; Misa Hirose; Yi Wang; Joshua M Thurman; V Michael Holers; B Paul Morgan; Jörg Köhl; Detlef Zillikens; Ralf J Ludwig; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

Review 10.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.